JP6655549B2 - 免疫応答を誘導するための新規方法 - Google Patents

免疫応答を誘導するための新規方法 Download PDF

Info

Publication number
JP6655549B2
JP6655549B2 JP2016560336A JP2016560336A JP6655549B2 JP 6655549 B2 JP6655549 B2 JP 6655549B2 JP 2016560336 A JP2016560336 A JP 2016560336A JP 2016560336 A JP2016560336 A JP 2016560336A JP 6655549 B2 JP6655549 B2 JP 6655549B2
Authority
JP
Japan
Prior art keywords
composition
months
adjuvant
administration
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016560336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511327A5 (enExample
JP2017511327A (ja
Inventor
ジェイアール，ウィリアム リプレイ バロー
ジェイアール，ウィリアム リプレイ バロー
デモワティ，マリー−アンジェ
レネレ ドナー，マリー−ノエル
レネレ ドナー，マリー−ノエル
オウアケド，ナディア
テオフイル テマーマン，シュテファン
テオフイル テマーマン，シュテファン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2017511327A publication Critical patent/JP2017511327A/ja
Publication of JP2017511327A5 publication Critical patent/JP2017511327A5/ja
Application granted granted Critical
Publication of JP6655549B2 publication Critical patent/JP6655549B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016560336A 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法 Expired - Fee Related JP6655549B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
GB1405921.6 2014-04-02
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511327A JP2017511327A (ja) 2017-04-20
JP2017511327A5 JP2017511327A5 (enExample) 2018-05-17
JP6655549B2 true JP6655549B2 (ja) 2020-02-26

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Country Status (18)

Country Link
US (3) US10688168B2 (enExample)
EP (2) EP3125930B1 (enExample)
JP (2) JP6655549B2 (enExample)
KR (2) KR20160132115A (enExample)
CN (2) CN106456739A (enExample)
AR (1) AR099960A1 (enExample)
AU (1) AU2015239025B2 (enExample)
BE (1) BE1022355B1 (enExample)
BR (2) BR112016022787A2 (enExample)
CA (2) CA2943007C (enExample)
EA (1) EA037405B1 (enExample)
ES (2) ES2961840T3 (enExample)
GB (1) GB201405921D0 (enExample)
IL (1) IL247493B (enExample)
MX (3) MX2016012932A (enExample)
SG (1) SG11201607086QA (enExample)
WO (2) WO2015150567A1 (enExample)
ZA (1) ZA201605955B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
EA016648B1 (ru) 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
HUE031411T2 (en) * 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2010010179A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
UA107330C2 (uk) * 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
EP2315597B1 (en) * 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
PL2528621T3 (pl) * 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
HUE028452T2 (en) * 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
BR112016022463A2 (pt) 2017-10-10
IL247493B (en) 2022-08-01
ES2853773T3 (es) 2021-09-17
EP3125929A1 (en) 2017-02-08
JP6645982B2 (ja) 2020-02-14
EP3125930A1 (en) 2017-02-08
BE1022355A1 (fr) 2016-02-16
BR112016022787A2 (pt) 2018-03-27
MX2016012932A (es) 2016-12-07
ES2961840T3 (es) 2024-03-14
BE1022355B1 (fr) 2016-03-26
EP3125930B1 (en) 2020-12-02
US11951161B2 (en) 2024-04-09
CA2943007C (en) 2024-01-09
CA2943007A1 (en) 2015-10-08
AU2015239025A1 (en) 2016-09-22
EA037405B1 (ru) 2021-03-25
KR20230075525A (ko) 2023-05-31
AR099960A1 (es) 2016-08-31
US10624961B2 (en) 2020-04-21
US20200306353A1 (en) 2020-10-01
CN106456739A (zh) 2017-02-22
US20170112914A1 (en) 2017-04-27
CN106456738A (zh) 2017-02-22
ZA201605955B (en) 2019-04-24
WO2015150567A1 (en) 2015-10-08
EA201691638A1 (ru) 2017-04-28
GB201405921D0 (en) 2014-05-14
KR20160132115A (ko) 2016-11-16
EP3125929C0 (en) 2023-11-01
IL247493A0 (en) 2016-11-30
SG11201607086QA (en) 2016-09-29
EP3125929B8 (en) 2023-12-27
JP2017511327A (ja) 2017-04-20
CA2943711A1 (en) 2015-10-08
EP3125929B1 (en) 2023-11-01
MX2016012982A (es) 2016-12-07
CN106456738B (zh) 2021-06-29
AU2015239025B2 (en) 2018-01-25
US10688168B2 (en) 2020-06-23
KR102762440B1 (ko) 2025-02-03
MX2022013912A (es) 2022-12-13
WO2015150568A1 (en) 2015-10-08
JP2017511324A (ja) 2017-04-20
US20170136110A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
JP5951634B2 (ja) マイコバクテリウム抗原性組成物
JP6655549B2 (ja) 免疫応答を誘導するための新規方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200203

R150 Certificate of patent or registration of utility model

Ref document number: 6655549

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees